Literature DB >> 2996659

Incidence of involvement of the B and T lymphocyte lineages in chronic myelogenous leukemia.

M Nitta, Y Kato, A Strife, M Wachter, J Fried, A Perez, S Jhanwar, R Duigou-Osterndorf, R S Chaganti, B Clarkson.   

Abstract

Peripheral blood specimens were obtained from 22 patients with Philadelphia chromosome (Ph1) positive chronic myelogenous leukemia (CML) (16 in chronic phase, 2 in an accelerated phase, and 4 in blast crisis). Studies were performed to determine the frequency of the presence of the Ph1 chromosome in cells of lymphoid lineages. Rosetted (E+) lymphocytes (T lymphocytes) from nine patients in chronic phase and one patient in blast crisis were stimulated with T cell growth factor interleukin 2 (IL-2) and/or phytohemagglutinin (PHA). All ten patients had sufficient T lymphocyte metaphases for analysis and of a total of 461 metaphases examined, only one contained the Ph1 chromosome. Nucleated cells of density less than 1.077 g/mL were infected with Epstein-Barr virus (EBV). Following infection, cell lines were established from individual colonies attached to egg albumin-coated Lab-Tek slide chambers (clonal cell lines) or from suspension culture in 96-well tissue culture cluster dishes (nonclonal cell lines). Cell surface and intracellular marker analysis confirmed the B lymphocyte phenotype of all the cell lines examined. B lymphoblastoid cell lines were established from 16 of the 22 patients. All lines from 12 patients were Ph1-negative. From two chronic phase patients, both Ph1-positive and Ph1-negative lines were established. From one patient in an accelerated phase, only Ph1-positive lines were established. From another patient in blast crisis (of myeloblastic phenotype), only Ph1-positive lines were established initially; however, five months later, after the patient had been treated with mitoxantrone, only Ph1-negative lines were derived from this patient. Based on these results, it appears that most B cells and mature T cells in most CML patients are Ph1-negative, but that about 25% of patients have predominantly Ph1-positive B cells or a mixture of Ph1-positive and Ph1-negative B cells that are capable of growing as established cell lines after transformation with EBV.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996659

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  7q-and loss of a polymorphism for the met oncogene in a patient with myelofibrosis.

Authors:  G Rege-Cambrin; A Guerrasio; A Serra; A Alfarano; A Stacchini; P Lusso; G Benetton; M Aglietta; M Bonetto; G Saglio
Journal:  Cytotechnology       Date:  1987-10       Impact factor: 2.058

2.  Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.

Authors:  K R LaMontagne; A J Flint; B R Franza; A M Pandergast; N K Tonks
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

3.  Variable expression of the translocated c-abl oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patients.

Authors:  J B Konopka; S Clark; J McLaughlin; M Nitta; Y Kato; A Strife; B Clarkson; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

4.  A 41-kilodalton protein is a potential substrate for the p210bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells.

Authors:  E Freed; T Hunter
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

Review 5.  Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia.

Authors:  Vivian G Oehler; Jerald P Radich
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

Review 6.  Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis.

Authors:  M R Corces-Zimmerman; R Majeti
Journal:  Leukemia       Date:  2014-07-09       Impact factor: 11.528

7.  The majority of T lymphocytes are polyclonal during the chronic phase of chronic myelogenous leukemia.

Authors:  N Tsukamoto; M Karasawa; T Maehara; K Okamoto; H Sakai; T Naruse; K Morita; J Tsuchiya; M Omine
Journal:  Ann Hematol       Date:  1996-02       Impact factor: 3.673

8.  Persistence of bcr-abl mRNA-expressing cells in long-term cultures established from chronic myeloid leukemic bone marrow or blood.

Authors:  G Pasternak; L Pasternak
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

9.  Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.

Authors:  Hanna L M Rajala; Mohamed El Missiry; Anniina Ruusila; Perttu Koskenvesa; Tim H Brümmendorf; Bjorn T Gjertsen; Jeroen Janssen; Kourosh Lotfi; Berit Markevärn; Ulla Olsson-Strömberg; Leif Stenke; Jesper Stentoft; Johan Richter; Henrik Hjorth-Hansen; Anna Kreutzman; Satu Mustjoki
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-23       Impact factor: 4.553

10.  p53 in chronic myelogenous leukemia. Study of mechanisms of differential expression.

Authors:  M Lübbert; C W Miller; L Crawford; H P Koeffler
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.